0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.211.190.232. Please contact the publisher to request reinstatement.
ARTICLE |

Immunotherapy for Melanoma

Robert Auerbach, MD
JAMA. 1973;226(13):1571. doi:10.1001/jama.1973.03230130059034.
Text Size: A A A
Published online

ABSTRACT

To the Editor.—  In the editorial "Immunotherapy for-Melanoma" (225:1242, 1973), there is the statement,Particularly gratifying are the results in leukoplakias, keratoses, and squamous and basal cell carcinomas, which have been frequently eradicated for five years or longer without recurrence.I think it should be pointed out that leukoplakias, keratoses, and squamous and basal cell carcinomas can be treated easily with available surgical techniques or radiation, without immunotherapy. The latter is more cumbersome and less certain to insure eradication. Fluororacil in the treatment of some of these lesions works by its cytotoxic action in premalignant lesions and poorly in malignant lesions, such as squamous cell carcinomas and basal cell carcinomas.It is in the treatment of melanoma that immunotherapy holds out the greatest hope and perhaps in mycosis fungoides, lymphomas, Kaposi sarcoma, and reticulum cell sarcoma.The basal cell carcinoma and squamous cell carcinoma have a cure rate of better

Topics

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Figures

Tables

References

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs
brightcove.createExperiences();